Phase III Study of Palbociclib (PD-0332991) in Combination With Endocrine Therapy (Exemestane or Fulvestrant) Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Aromatase Inhibitors

Trial Profile

Phase III Study of Palbociclib (PD-0332991) in Combination With Endocrine Therapy (Exemestane or Fulvestrant) Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Aromatase Inhibitors

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2018

At a glance

  • Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PEARL
  • Most Recent Events

    • 04 Jan 2018 Planned number of patients changed from 600 to 596.
    • 09 Dec 2017 Results (n=26) of pharmacokinetic substudy evaluating drug interaction potential of palbociclib and exemestane presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 05 Aug 2017 This trial has been completed in Ireland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top